382 related articles for article (PubMed ID: 33500635)
1. Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales.
Tan X; Kim HS; Baugh K; Huang Y; Kadiyala N; Wences M; Singh N; Wenzler E; Bulman ZP
Infect Drug Resist; 2021; 14():125-142. PubMed ID: 33500635
[TBL] [Abstract][Full Text] [Related]
2. The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases.
Mauri C; Maraolo AE; Di Bella S; Luzzaro F; Principe L
Antibiotics (Basel); 2021 Aug; 10(8):. PubMed ID: 34439062
[TBL] [Abstract][Full Text] [Related]
3. Clinical Features and Outcomes of Infections Caused by Metallo-β-Lactamase-Producing Enterobacterales: A 3-Year Prospective Study From an Endemic Area.
Falcone M; Giordano C; Leonildi A; Galfo V; Lepore A; Suardi LR; Riccardi N; Barnini S; Tiseo G
Clin Infect Dis; 2024 May; 78(5):1111-1119. PubMed ID: 38036465
[TBL] [Abstract][Full Text] [Related]
4. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing
Bhatnagar A; Boyd S; Sabour S; Bodnar J; Nazarian E; Peinovich N; Wagner C; Craft B; Snippes Vagnone P; Simpson J; Stone VN; Therrien M; Bateman A; Lower D; Huang JY; Gumbis S; Lonsway D; Lutgring JD; Karlsson M; Brown AC
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0048621. PubMed ID: 34060895
[TBL] [Abstract][Full Text] [Related]
5.
Wang W; Huang S; Zou C; Ding Y; Wang H; Pu S; Liao Y; Du H; Wang D; Chen L; Niu S
Front Cell Infect Microbiol; 2021; 11():755763. PubMed ID: 34778107
[TBL] [Abstract][Full Text] [Related]
6. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
Lee M; Abbey T; Biagi M; Wenzler E
Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
[TBL] [Abstract][Full Text] [Related]
7.
Cervino I; Gonzalez D; Nastro M; Vega J; Reyes AP; Buriano G; Vay C; Famiglietti A; Rodriguez CH
J Med Microbiol; 2021 Oct; 70(10):. PubMed ID: 34605763
[TBL] [Abstract][Full Text] [Related]
8. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
9. Metallo-beta-lactamases: mechanisms, treatment challenges, and future prospects.
Zakhour J; El Ayoubi LW; Kanj SS
Expert Rev Anti Infect Ther; 2024 Apr; 22(4):189-201. PubMed ID: 38275276
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Severe Infections Due to Metallo-Betalactamases
Timsit JF; Wicky PH; de Montmollin E
Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203747
[TBL] [Abstract][Full Text] [Related]
11. Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive
Zalacain M; Lozano C; Llanos A; Sprynski N; Valmont T; De Piano C; Davies D; Leiris S; Sable C; Ledoux A; Morrissey I; Lemonnier M; Everett M
Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33820763
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of aztreonam-avibactam against metallo-β-lactamase-producing Enterobacteriaceae-A multicenter study in China.
Zhang B; Zhu Z; Jia W; Qu F; Huang B; Shan B; Yu H; Tang Y; Chen L; Du H
Int J Infect Dis; 2020 Aug; 97():11-18. PubMed ID: 32473388
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
Falcone M; Daikos GL; Tiseo G; Bassoulis D; Giordano C; Galfo V; Leonildi A; Tagliaferri E; Barnini S; Sani S; Farcomeni A; Ghiadoni L; Menichetti F
Clin Infect Dis; 2021 Jun; 72(11):1871-1878. PubMed ID: 32427286
[TBL] [Abstract][Full Text] [Related]
14. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018.
Kiratisin P; Kazmierczak K; Stone GG
J Glob Antimicrob Resist; 2021 Dec; 27():132-141. PubMed ID: 34478880
[TBL] [Abstract][Full Text] [Related]
16. Screening for Metallo-Beta-Lactamases Using Non-Carbapenem Agents: Effective Detection of MBL-Producing
Takei K; Kanamori H; Nakayama A; Chiba M; Takei Y; Seike I; Kitamura C; Baba H; Oshima K; Tokuda K
Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508242
[TBL] [Abstract][Full Text] [Related]
17. ZN148 Is a Modular Synthetic Metallo-β-Lactamase Inhibitor That Reverses Carbapenem Resistance in Gram-Negative Pathogens
Samuelsen Ø; Åstrand OAH; Fröhlich C; Heikal A; Skagseth S; Carlsen TJO; Leiros HS; Bayer A; Schnaars C; Kildahl-Andersen G; Lauksund S; Finke S; Huber S; Gjøen T; Andresen AMS; Økstad OA; Rongved P
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32179522
[TBL] [Abstract][Full Text] [Related]
18. Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing
Merad Y; Conrad A; Brosset S; Schmidt A; Hanriat C; Lustig S; Laurent F; Kolenda C; Roussel-Gaillard T; Batailler C; Ferry T;
Front Med (Lausanne); 2023; 10():1224922. PubMed ID: 37601796
[TBL] [Abstract][Full Text] [Related]
19. A Case of New Delhi Metallo-β-Lactamases (NDM) Citrobacter sedlakii Osteomyelitis Successfully Treated With Ceftazidime-Avibactam and Aztreonam.
Rubnitz ZA; Kunkel VN; Baselski VS; Summers NA
Cureus; 2022 Sep; 14(9):e28855. PubMed ID: 36225496
[TBL] [Abstract][Full Text] [Related]
20. Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools.
Verschelden G; Noeparast M; Stoefs A; Van Honacker E; Vandoorslaer K; Vandervore L; Olbrecht M; Van Damme K; Demuyser T; Piérard D; Wybo I
Front Microbiol; 2023; 14():1322180. PubMed ID: 38094627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
